In this episode we're joined by Dr Stefan Nilsson, founder and CEO of Lipigon Pharmaceuticals, where he discusses the challenges and opportunities in treating metabolic diseases such as dyslipidemia. We also go on to discuss how Lipigon operates as a virtual biotech, allowing it to remain nimble in its efforts to develop novel therapies against a wide range of diseases. 

Lipigon was founded in 2010 based on over 50 years of research in lipid biology at Umea University in Sweden. Lipigon develops novel therapeutics for patients with lipid metabolism disorders, and is currently focusing on orphan drugs for rare diseases. There are currently four active projects in Lipigon’s pipeline, including RNA drugs, a gene therapy treatment and a small molecule program. Prior to founding Lipigon, Dr Nilsson was a researcher at Umea University, where he led a group focusing on metabolic disease and was involved with the Umea Biotech Incubator. In addition to this, Stefan has many years of experience working in the pharmaceutical and biotechnology industries, and currently sits on the board of Omnio.